Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in man phase I trial of NPM-139 for Obesity

Trial Profile

A first in man phase I trial of NPM-139 for Obesity

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Semaglutide
  • Indications Obesity
  • Focus Adverse reactions; First in man

Most Recent Events

  • 24 Oct 2025 New trial record
  • 04 Sep 2025 According to a Vivani Medical media release, the company plans to initiate a Phase 1 clinical study in the NPM-139 semaglutide implant program in the first half of 2026, pending regulatory clearance.
  • 13 Aug 2025 According to a Vivani Medical media release, the company anticipates providing a more detailed update on the NPM-139 program later this year, including the proposed design of the clinical program and the dose-ranging weight maintenance study outcomes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top